ProPhase Labs (NASDAQ:PRPH) Price Target Raised to $15.00 at HC Wainwright

ProPhase Labs (NASDAQ:PRPH) had its price target raised by HC Wainwright from $12.00 to $15.00 in a research report report published on Friday, Price Targets.com reports. The firm currently has a buy rating on the stock.

A number of other analysts have also commented on PRPH. Zacks Investment Research lowered ProPhase Labs from a buy rating to a hold rating in a report on Thursday. Dawson James downgraded ProPhase Labs from a buy rating to a neutral rating in a research note on Wednesday, October 13th.

NASDAQ PRPH opened at $7.30 on Friday. ProPhase Labs has a fifty-two week low of $4.41 and a fifty-two week high of $16.04. The company has a current ratio of 4.42, a quick ratio of 3.56 and a debt-to-equity ratio of 0.21. The stock has a 50 day simple moving average of $6.80 and a two-hundred day simple moving average of $6.19.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Friday, November 12th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.33). The company had revenue of $9.47 million for the quarter, compared to the consensus estimate of $9.08 million. ProPhase Labs had a negative net margin of 13.56% and a negative return on equity of 5.84%. During the same period last year, the business earned ($0.05) EPS. On average, sell-side analysts expect that ProPhase Labs will post -0.27 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in ProPhase Labs by 261.2% during the second quarter. Vanguard Group Inc. now owns 466,338 shares of the company’s stock valued at $2,891,000 after purchasing an additional 337,232 shares in the last quarter. Perritt Capital Management Inc. lifted its position in shares of ProPhase Labs by 5.9% in the third quarter. Perritt Capital Management Inc. now owns 188,400 shares of the company’s stock valued at $980,000 after acquiring an additional 10,500 shares in the last quarter. Kamunting Street Capital Management L.P. lifted its position in shares of ProPhase Labs by 26.0% in the second quarter. Kamunting Street Capital Management L.P. now owns 123,193 shares of the company’s stock valued at $764,000 after acquiring an additional 25,400 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of ProPhase Labs by 3.1% in the third quarter. Geode Capital Management LLC now owns 105,857 shares of the company’s stock valued at $550,000 after acquiring an additional 3,152 shares in the last quarter. Finally, Avidian Wealth Solutions LLC lifted its position in shares of ProPhase Labs by 91.4% in the third quarter. Avidian Wealth Solutions LLC now owns 105,202 shares of the company’s stock valued at $547,000 after acquiring an additional 50,239 shares in the last quarter. Institutional investors own 10.62% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc is a medical science and technology company. It engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The firm operates through the following business segments: Diagnostic Services and Consumer Products.

Further Reading: How does inflation affect different investments?

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.